Drug evaluation: zanolimumab, a human monoclonal antibody targeted against CD4.
Merck Serono SA, under license from Genmab A/S and Medarex Inc, is developing zanolimumab, a human mAb targeted against CD4, for the potential treatment of cutaneous (CTCL) and noncutaneous (NCTCL) T-cell lymphomas. Zanolimumab is currently undergoing phase III clinical trials for CTCL and phase II clinical trials for NCTCL.
Assaf
Chalid
C
Skin Cancer Center Charité, Department of Dermatology, Venereology and Allergy, Charité-Universitätsmedizin Berlin, Fabeckstr 60-62, 14195 Berlin, Germany. chalid.assaf@charite.de
Sterry
Wolfram
W
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D015704:CD4 Antigens / Q000276:immunology*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D000075202:Contraindications; D004353:Drug Evaluation, Preclinical; D006801:Humans; D010330:Patents as Topic; D013329:Structure-Activity Relationship
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015704:CD4 Antigens; C520522:zanolimumab